Loxo Oncology Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Loxo Oncology (LOXO) Prices 1.68M Common Stock Offering at $21.50/Share
May 12, 2016 9:51 AM EDTLoxo Oncology, Inc. (Nasdaq: LOXO) announced the pricing of its underwritten public offering of 1,675,000 shares of common stock at a public offering price of $21.50 per share. Gross proceeds to Loxo Oncology from this offering are expected to be approximately $36 million. Loxo Oncology intends to use the net proceeds from this offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own, and capital expenditures.
Loxo Oncology also has granted the underwriters a 30-day... More
